STF 31 |
Catalog No.GC14803
One-Click Copy Product Info
|
STF 31 is a cell-permeable inhibitor of glucose transporter 1 (GLUT1) with an IC₅₀ of 1μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 724741-75-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
STF 31 is a cell-permeable inhibitor of glucose transporter 1 (GLUT1) with an IC₅₀ of 1μM[1]. GLUT1 is a key transporter responsible for glucose uptake and plays an essential role in maintaining glycolytic metabolism[2]. STF 31 can inhibit nicotinamide phosphoribosyltransferase (NAMPT), thereby disrupting glycolysis and inducing cytotoxicity[3].
In vitro, STF 31 (0-10μM) treatment inhibited the glucose uptake capacity of B6M7 cells in a dose-dependent manner within 24h without significantly affecting cell viability[4]. STF 31 (30μM) treatment of MCF-7 cells for 48h significantly suppressed glycolysis and induced apoptosis[5]. STF 31 (2, 4, and 8μM) treatment of rheumatoid arthritis fibroblast-like synoviocytes (RAFLs) for 24-72h inhibited cell proliferation in a time- and dose-dependent manner[6].
In vivo, STF 31 (10mg/kg), administered via intraperitoneal injection (twice daily for the first 2 days, followed by once daily for the next 3 days), had no significant effects on body weight, behavior, or ERG responses in normal mice. In a light-induced model, STF 31 significantly inhibited microglial activation in CX3CR1gfp/+ mice and alleviated retinal degeneration[4]. Intraperitoneal co-administration of STF 31 (10mg/kg) and dexamethasone in normal mice for 4h significantly promoted the accumulation of necrotic thymocytes[7].
References:
[1] Chan D A, Sutphin P D, Nguyen P, et al. Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality[J]. Sci Transl Med, 2011, 3(94).
[2] Wu Q, ba-alawi W, Deblois G, et al. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer[J]. Nat Commun, 2020, 11(1).
[3] Adams D J, Ito D, Rees M G, et al. NAMPT Is the Cellular Target of STF 31-Like Small-Molecule Probes[J]. Acs Chem Biol, 2014, 9(10): 2247-2254.
[4] Wang L X, Pavlou S, Du X, et al. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis[J]. Mol Neurodegener, 2019, 14.
[5] Xintaropoulou C, Ward C, Wise A, et al. A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models[J]. Oncotarget, 2015, 6(28): 25677-25695.
[6] Hou Hou, Lü Xing, Zhang Na, et al. Mechanism Analysis of the Effect of STF 31 on Proliferation and Apoptosis of Fibroblast-like Synoviocytes in Rheumatoid Arthritis [J]. Anatomical Research, 2022, 44(06): 525-531
[7] Morioka S, Perry JSA, Raymond MH, et al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release[J]. Nature, 2018, 563(7733): 714-718.
| Cell experiment [1]: | |
Cell lines | B6M7 |
Preparation Method | B6M7 cells were seeded into 96-well plates with 6000 cells per well and cultured for 24h. They were treated with different concentrations of STF 31(0, 0.01, 0.1, 1, 5, and 10μM).for 24 h to 48 h.Cells were washed twice with PBS and incubated in serum-free DMEM overnight prior to the assay. Glucose uptake was measured using a Glucose Uptake Assay Kit (ab136955, Abcam) according to the manufacturer’s instructions, and fluorescence was detected using a FLUOstar Omega microplate reader (BMG Labtech). Cell viability was assessed using the AlamarBlue® assay (Thermo Fisher Scientific) following the manufacturer’s protocol. |
Reaction Conditions | 0, 0.01, 0.1, 1, 5, and 10μM; 24 h, 48 h. |
Applications | STF 31 dose-dependently suppressed glucose uptake in B6M7 cells without affecting cell viability. |
| Animal experiment [1]: | |
Animal models | C57BL/6J and CX3CR1gfp/+ mice |
Preparation Method | C57BL/6 J mice received intraperitoneal STF 31 at 10 mg/kg twice daily for 2 days and once daily for a further 3 days, with DMSO-treated mice as controls. Body weight and electroretinography were assessed on day 6, and eyes were collected for immunohistochemistry (4 mice per group). CX3CR1gfp/+mice were given the same STF 31 regimen starting 1 day prior to light exposure. After 16 h of dark adaptation, pupil dilation, and anesthesia, mice were exposed to 50,000 lx focal white light for 10 min. Clinical and immunohistochemical analyses were performed after treatment (5 mice per group). |
Dosage form | 10mg/kg, twice daily for 2 days, followed by once daily for another 3 days; i.p. |
Applications | STF 31 treatment improved photoreceptor survival and attenuated microglial activation in CX3CR1gfp/+ mice, without inducing retinal cell death in C57BL/6J mice. |
References: | |
| Cas No. | 724741-75-7 | SDF | |
| Chemical Name | 4-((4-(tert-butyl)phenylsulfonamido)methyl)-N-(pyridin-3-yl)benzamide | ||
| Canonical SMILES | O=S(NCC1=CC=C(C(NC2=CC=CN=C2)=O)C=C1)(C3=CC=C(C=C3)C(C)(C)C)=O | ||
| Formula | C23H25N3O3S | M.Wt | 423.53 |
| Solubility | ≥ 42.4mg/mL in DMSO | Storage | Store at RT |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3611 mL | 11.8055 mL | 23.6111 mL |
| 5 mM | 472.2 μL | 2.3611 mL | 4.7222 mL |
| 10 mM | 236.1 μL | 1.1806 mL | 2.3611 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)